Articles about COVAXIN Phase III Trial
03 Jul 2021
COVAXIN overall 77.8% effective in Phase-3 trial, says Bharat Biotech
COVAXIN, the coronavirus vaccine developed by India's Bharat Biotech, is overall 77.8 percent effective, the company said in a statement today, sharing the final analysis of its phase three trial data.
22 Jun 2021
Bharat Biotech submits COVAXIN phase-3 trial data, review meet today
Bharat Biotech has submitted the phase three clinical trial data for its coronavirus vaccine COVAXIN to the Drugs Controller General of India (DCGI).
11 Jun 2021
FDA rejects emergency-use approval of Bharat Biotech's COVAXIN
The United States' top drug regulator - the Food and Drug Administration - has rejected Bharat Biotech's application for an emergency use authorization for its COVID-19 vaccine COVAXIN.